Katherine Talcott, MD

Retina Specialist at the Cole Eye Institute at the Cleveland Clinic

Articles by Katherine Talcott, MD

VERONA: Katherine Talcott, MD, on early gains with a TKI insert in DME

ByKatherine Talcott, MD,Kassi Filkins,Martin David Harp

November 11th 2026

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME

EURETINA 2026: EYP-1901 reduces need for supplemental treatment in phase 2 VERONA study of DME

ByKatherine Talcott, MD,Martin David Harp

October 2nd 2026

Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment needs in DME, with early vision and anatomy gains and no significant safety signals.

Katherine Talcott, MD

Articles by Katherine Talcott, MD

VERONA: Katherine Talcott, MD, on early gains with a TKI insert in DME

EURETINA 2026: EYP-1901 reduces need for supplemental treatment in phase 2 VERONA study of DME

Latest Updated Articles

Trending on Eye Care Network - Ophthalmology Times

FDA requires NAION warning across the GLP-1 receptor agonist class

VERONA: Katherine Talcott, MD, on early gains with a TKI insert in DME

Viridian's VRDN-008 sustains IgG suppression through 8 weeks in phase 1

Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia

The One Thing: GA’s last frontier, the toll of ongoing care, back to glucose basics | Episode 6